AXSM250117C120000
- 0.08
- 0.000.00%
Axsome Therapeutics Newsroom
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $133
Axsome Therapeutics: Strong Buy Recommendation Driven by Promising Pipeline and Market Expansion
Axsome Therapeutics Analyst Ratings
William Blair Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Alzheimer's Drug Study Yields Mixed Results. Wall Street Still Likes Axsome
Axsome Therapeutics Price Target Cut to $122.00/Share From $124.00 by Mizuho
Axsome Therapeutics Is Maintained at Outperform by Mizuho
Express News | Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $122
Axsome Therapeutics Mixed Alzheimer's Disease Agitation Data Disappoints but Approvability Seen Likely, Mizuho Says
Leerink Partners Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $110
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $124
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $180
Truist Says 'Aggressive' Buying Axsome Therapeutics After AXS-05 ADA Data
Express News | HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Buy Rating for Axsome Therapeutics: Promising AXS-05 Efficacy in Alzheimer's Agitation
RBC Capital Adjusts Price Target on Axsome Therapeutics to $138 From $132, Keeps Outperform Rating